Annexon reports Q2 2026 results, sets tanruprubart BLA for fourth quarter

Annexon, Inc. reported second quarter 2026 results on August 12, 2026, alongside updates across its three clinical programs.

For tanruprubart in Guillain-Barré syndrome, the company said the first ten U.S. and European patients in the ongoing, open-label FORWARD study showed early improvement in strength and clinically meaningful reduction in disability.¹ Annexon said these early outcomes reinforce the consistency and reproducibility of tanruprubart treatment effect previously demonstrated in Phase 3 and real-world evidence studies.¹ The company also noted an EU Marketing Authorisation Application is under review with the European Medicines Agency, supported by a data package showing rapid benefit on function and disability in placebo-controlled studies and real-world evidence showing favorable outcomes versus intravenous immunoglobulin and plasma exchange.¹ Annexon said its next milestone is a Biologics License Application submission using U.S. and European data from the FORWARD trial, expected in the fourth quarter of 2026.¹

In geographic atrophy, the Phase 3 ARCHER II trial of vonaprument remains on track, with all eligible patients having received at least 12 months of treatment and masked event accrual consistent with projected timelines.¹ Annexon added a Month 24 dual primary endpoint while keeping the Month 15 primary endpoint, so the trial can show success in protecting against vision loss at either timepoint.¹ The company said the Month 15 readout is expected in the fourth quarter of 2026, and it separately said full trial completion, covering the added Month 24 endpoint, is anticipated for the third quarter of 2027, according to the release.

For ANX1502 in cold agglutinin disease, dosing in the proof-of-concept study is complete, with an update expected in the fall of 2026.¹

On financing, Annexon entered a credit facility of up to $200 million with Oxford Finance LLC, with $50 million drawn at closing.¹ Cash, equivalents and short-term investments totaled $209.2 million as of June 30, 2026,¹ and the company said this position plus facility funds are expected to fund operations and anticipated milestones into 2028.¹